A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
Status:
Active, not recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in
combination with RASi(ACEI and/or ARB) compared with RASi.
Phase:
Phase 4
Details
Lead Sponsor:
XIEJINGYUAN
Collaborators:
Dongfang Hospital Affiliated to Tongji University Ningbo Municipal Yinzhou District No.2 Hospital Ruijin Hospital North Shanghai Jiao Tong University School of Medicine Shanghai Pudong New Area People's Hospital Sir Run Run Shaw Hospital Third Affiliated Hospital, Sun Yat-Sen University Xiamen Hongai Hospital